The clinical role of long-acting β2-agonists in COPD

Respiratory Medicine

Volumn 94, Issue SUPPL. E, 2000, Pages

  Kips, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CATHEPSIN G; CHOLINERGIC RECEPTOR BLOCKING AGENT; ELAFIN; ELASTASE; FORMOTEROL; IMMUNOGLOBULIN A; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MATRIX METALLOPROTEINASE; MYELOBLASTIN; OXITROPIUM BROMIDE; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR; PYOCYANINE; SALMETEROL; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE; STEROID; TERBUTALINE;

ARTICLE; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EOSINOPHIL; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LUNG FUNCTION; POWDER INHALER; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY AIRFLOW; VITAL CAPACITY;

EID: 0033799327     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2000.0849     Document Type: Article

References (46)

1. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
2. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease
3. Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease
4. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting
5. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease
6. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease
7. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
8. A placebo-controlled comparison of the effects of formoterol and ipratropium bromide in patients with COPD
9. Effects of treatment with formoterol on bronchoprotection against methacholine
10. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: A single centre randomised, double blind, placebo controlled, crossover study
11. Quality of life changes in COPD patients treated with salmeterol
12. Effect of inhaled formoterol and ipratropium bromide on quality of life, ″bad days″ and excaerbations in patients with COPD
13. Site and nature of airway obstruction in chronic obstructive lung disease
14. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease
15. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease
16. Salmeterol versus formoterol in patients with moderately severe asthma : Onset and duration of action
17. On demand treatment : Comparison of formoterol and terbuatine in moderate asthma
18. Bronchodilator reversibility, exercise performance and breathelessness in stable chronic obstructive pulmonary disease
19. The effects of formoterol on exercise capacity in COPD patients
20. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease
21. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
22. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease
23. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis
24. Intraluminal airway inflammation in chronic bronchitis
25. Severity of airflow limitation is associated with severity of airway inflammation in smokers
26. Chronic obstructive pulmonary disease (COPD)
27. Role of bacteria in the pathogenesis and progression of acute and chronic lung function
28. Beta2-agonist-induced inhibition of neutrophil chemotaxis is not associated with modification of LFA-1 and Mac-1 expression or with impairment of polymorphonuclear leukocyte antibacterial activity
29. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa
30. Airway eosinophils in chronic bronchitis during exacerbations
31. Salmeterol is a competitive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils
32. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma
33. Efficacy of salmeterol xinafoate in the treatment of COPD
34. 1
35. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro
36. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
37. The natural history of chronic airflow obstruction
38. Long-term treatment with inhaled budesonide in persons wild mild chronic obstructive pulmonary disease who continue smoking
39. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
40. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base
41. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone
42. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD
43. Efficacy and safety of salmeterol (SLM) and ipratropium bromide (IPB) in patients with chronic obstructive pulmonary disease (COPD)
44. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator : A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group
45. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma